Guntern Takes Lead At Medicines For Europe
Sandoz Executive Becomes Interim President After Teva’s Stoller Completes Two-Year Term
Executive Summary
Sandoz’s Rebecca Guntern has been named as interim president of Medicines for Europe for a three-month term, after Teva’s Christoph Stoller stepped down at the end of his two-year tenure.
You may also be interested in...
Musical Chairs For Off-Patent Executives In 2021
Last year was a year of significant executive changes in the off-patent industry, with numerous high-profile hires and departures from companies like Sandoz, Teva, Viatris, Hikma, Fresenius, Neuraxpharm and Stada.
Central Role For Industry Beckons As Europe Rebuilds After COVID
Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.
Off-Patent Industry Must Become ‘Focal Point’ For Health Systems Post-COVID
Off-patent medicines must become the “focal point” of pharmaceutical policies across the world as health systems recover from the COVID-19 pandemic, Medicines for Europe and the IGBA have urged as they held their joint annual conference in Athens, Greece.